According to a decision by the Annual General Meeting on December 18, 2019, the principles for the appointment of the Nomination Committee's members and instructions for the Nomination Committee adopted in 2018 will apply unchanged until the next Annual General Meeting. This means that CELLINK AB (CELLINK) shall have a nomination committee consisting of five members, one of whom shall be the Chairman of the Board. Other members shall be appointed by the four largest shareholders in the company as of the end of May, on the basis of a list of registered shareholders provided by Euroclear Sweden AB and other reliable information that has been available to the company.
The following have been appointed to be part of CELLINK's Nomination Committee in preparation for the 2021 Annual General Meeting:
- Rolf Classon, nominated by Erik Gatenholm
- Claes Dinkelspiel, nominated by Hector Martinez
- Malin Björkmo, nominated by Handelsbanken Fonder
- Jannis Kitsakis, nominated by Fjärde AP-fonden
- Carsten Browall, Chairman of the Board of CELLINK AB
The Annual General Meeting of CELLINK AB will be held at 4 PM on April 26, 2021 in Gothenburg. Shareholders who wish to submit proposals to CELLINK's Nomination Committee can do so via e-mail to: [email protected] (“To the Nomination Committee”) or letter to: CELLINK AB, Att: The Nomination Committee, Arvid Wallgrens backe 20, 413 46 Gothenburg, no later than January 31, 2021.
For further information, please contact:
Erik Gatenholm, CEO Gusten Danielsson, CFO
Phone (Sweden): +46 73 267 00 00 Phone (Sweden): +46 70 991 86 04
Phone (US): +1 (650) 515 5566 Phone (US): +1 (857) 332 2138
Email: [email protected] Email: [email protected]
This information was submitted for publication, through the agency of the contact persons set out above, on October 20, 2020 at 08:30 CET.
Founded in 2016, CELLINK is a global life-science company that provides technologies, products and services to create, understand and master biology. With a focus on the application areas of bioprinting, analysis, and liquid handling and bioprocessing, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical and cosmetic industries. CELLINK’s products are trusted by more than 1,800 laboratories, including ones at all the top 20 pharmaceutical companies, are being used in more than 60 countries, and have been cited in more than 200 publications. CELLINK is creating the future of medicine.
Visit cellink.com to learn more. CELLINK is listed on the Nasdaq Stockholm Main Market under CLNK B.